Global Partnership for Chikungunya Vaccine Development
The ACT-CHIK consortium brings together seven (7) leading partner institutions across four continents, uniting leading research institutions, universities, public health organizations, and clinical trial centres across Africa, Europe, Asia, and South America. Together, the partners combine world-class expertise in vaccine research, clinical trials, manufacturing, regulatory science, technology transfer, and community engagement to accelerate the development and evaluation of a safe and effective chikungunya vaccine for populations at risk, contributing to stronger global health security and pandemic preparedness.
- 🌍 4 Continents
- 🏛 7 Institutions
- 👩🔬 Hundreds of Researchers
- 💉 One Vaccine Mission
Institut Pasteur; Paris, France
Project coordinator, developer of the MV-CHIK vaccine platform.
Lead: Dr. Sotiris Missailidis
University of Rwanda; Kigali, Rwanda
Scientific project leadership; clinical trial site.
Lead: Dr.Anh Wartel/Prof.Leon Mutesa
Institut Pasteur de Dakar; Dakar, Senegal
Vaccine technology transfer recipient; clinical laboratory assays; clinical trial site.
Lead: Dr.Joe Fitchett
Fundação Oswaldo Cruz – Fiocruz; Rio de Janeiro, Brazil
Clinical trial material manufacturing (fill & finish); technology transfer support.
Lead: Dr.Hugo Defendi
Irrua Specialist Teaching Hospital; Irrua, Nigeria
Clinical trial site; Coordinating Principal Investigator.
Lead: Dr.Sylvanus Okogbenin
Kenya Medical Research Institute (KEMRI); Nairobi, Kenya
Clinical trial site; Lead of data dissemination and communication.
Lead: Dr.John Waitumbi
International Vaccine Institute – IVI; Seoul, South Korea
Clinical trial sponsor, regulatory strategy and capacity building.
Lead:Dr.Jessica Cowden